Our patient cohort included early breast cancer patients with high-risk characteristics: half were premenopausal, the majority had ≥4 positive axillary lymph nodes, large tumor size in most cases, almost half had high grade tumors, while 18.5% had ER/PgR-negative and 21.8% HER2-positive tumors. The gene discussed is ERBB2; the disease is breast carcinoma.